🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Genetic Obesity

    phase 2 small molecule completed

    2 trials

  2. Single Site Pacing

    Rhythm Pharmaceuticals Netherlands B.V.

    Acute Myocardial Infarction

    phase 2 other completed

    1 trial

  3. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  4. TAS-205

    Taiho Pharma Netherlands B.V.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  5. TAS-303

    Taiho Pharma Netherlands B.V.

    Stress Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  6. Tagraxofusp

    Stemline Therapeutics B.V.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  7. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Disorder

    phase 2 small molecule completed

    1 trial

  8. Tebapivat

    Agios Netherlands B.V.

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  9. Tebapivat

    Agios Netherlands B.V.

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  10. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  11. Tideglusib

    Rhythm Pharmaceuticals Netherlands B.V.

    Arrhythmogenic Cardiomyopathy

    phase 2 small molecule active

    1 trial

  12. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  13. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial

  14. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  15. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Onychomycosis of Toenail

    phase 2 small molecule active

    1 trial

  16. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  17. VCA-894A

    Vanda Pharmaceuticals Netherlands B.V.

    Charcot Marie Tooth Disease (CMT)

    phase 2 small molecule active

    1 trial

  18. VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Circadian Rhythm Sleep Disorders

    phase 2 small molecule completed

    1 trial

  19. VIR-2218

    Alnylam Netherlands B.V.

    Chronic Hepatitis B

    phase 2 small molecule completed

    2 trials

  20. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  21. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  22. VLY-686 (Tradipitant)

    Vanda Pharmaceuticals Netherlands B.V.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  23. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Performance Anxiety

    phase 2 small molecule completed

    1 trial

  24. VSF-173

    Vanda Pharmaceuticals Netherlands B.V.

    Excessive Somnolence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources